First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal range; Third subject was recently transplanted and is on trajectory...Read more
KarXT demonstrated a statistically significant 9.2-point reduction in PANSS Total score from baseline at Week 5 compared to placebo (p=0.0014) Trial also met all secondary endpoints, demonstrating statistically significant reductions in positive and negative symptoms of schizophrenia,...Read more
TORONTO, ON / ACCESSWIRE / October 29, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary,...Read more
Germantown, Maryland, and Venlo, the Netherlands, Oct. 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to...Read more
Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasis Grifols surgical bleeding management treatments form part of an increasingly robust portfolio of innovative therapeutics enhancing the...Read more
CLEVELAND, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA or Agency) for prademagene zamikeracel (pz-cel), its investigational...Read more
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| PROCEPT BioRobotics | 22.23 32.33 | $91.00 |
| ICON | 10.03 4.55 | $230.50 |
| Finch Therapeutics | 9.95 552.78 | $11.75 |
| Bio-Rad Laboratories | 8.36 2.61 | $328.59 |
| Madrigal Pharmaceuticals | 6.33 3.00 | $217.00 |
| Vera Therapeutics | 6.25 15.21 | $47.34 |
| Chemed | 5.87 0.97 | $608.85 |
| Monte Rosa Therapeutics | 4.59 93.87 | $9.48 |
| BeiGene | 4.41 2.07 | $217.22 |
| Charles River Laboratories | 4.40 2.42 | $186.52 |
| Instil Bio | 4.23 13.62 | $35.29 |
| Kazia Therapeutics | 4.14 796.15 | $4.66 |
| Avalon GloboCare | 4.07 1,769.57 | $4.30 |
| Penumbra | 4.03 1.97 | $208.74 |
| Glaukos | 3.49 2.67 | $134.08 |
| Biogen | 3.32 1.83 | $185.01 |
| Stryker | 3.19 0.90 | $356.01 |
| Natera | 3.04 2.58 | $120.71 |
| Company | Volume | Last Trade |
|---|---|---|
| Healthcare Triangle | 144,636,943 | $1.30 |
| Monte Rosa Therapeutics | 94,850,892 | $9.48 |
| Vyome | 36,361,564 | $0.22 |
| ImmunityBio | 30,777,250 | $6.17 |
| Pfizer | 28,258,907 | $28.86 |
| MIRA Pharmaceuticals | 22,998,655 | $1.57 |
| Viracta Therapeutics | 22,656,896 | $0.23 |
| Evoke Pharma | 20,992,565 | $7.08 |
| Genprex | 18,406,353 | $2.74 |
| Sangamo Therapeutics | 17,967,374 | $2.04 |
| Walgreens Boots Alliance | 16,164,789 | $9.44 |
| Tonix Pharmaceuticals | 15,471,471 | $0.18 |
| CNS Pharmaceuticals | 13,508,977 | $0.15 |
| Iterum Therapeutics | 13,079,258 | $1.43 |
| Therapeutic Solutions | 12,881,634 | $0.0009 |
| ImmunoPrecise Antibodies | 12,852,610 | $0.58 |
| Qualigen Therapeutics | 10,915,499 | $0.11 |
| Revance Therapeutics | 8,867,391 | $5.90 |
| Edwards Lifesciences | 8,144,324 | $68.52 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
